{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:06:07Z","timestamp":1783008367476,"version":"3.54.5"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The role of anticoagulation for stroke prevention in patients with device-detected atrial high-rate episodes, also known as subclinical atrial fibrillation (AF), is a subject of equipoise.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the net benefit of nonvitamin K antagonist oral anticoagulants (NOACs) in patients with device-detected subclinical AF.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Decision analytical model run with 10 000 patients with anticoagulation and 10 000 patients without anticoagulation in a clinical scenario of deciding whether to start NOACs for stroke prevention in patients with subclinical AF. A Markov decision model was conducted on October 1, 2024, to estimate net outcomes of NOACs. The patients had stroke risk and bleeding risks similar to those of patients in randomized trials of anticoagulation in subclinical AF.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Anticoagulation was modeled to decrease the risk of ischemic stroke by 32% and increase the risk of major bleeding by 62%. In probabilistic sensitivity analyses, the 95% CIs for treatment effect sizes were also considered.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome measure for overall net benefit was the cumulative quality-adjusted life-years (QALYs) during the simulation. The model considered the number and severity of ischemic strokes, hemorrhagic strokes, other intracranial bleeds, and extracranial bleeds, as well as the number of deaths during a 10-year simulation.<\/jats:p><\/jats:sec>Results<\/jats:title>When comparing the 2 cohorts of 10 000 patients (mean age, 77 years; 3700 [37%] women), those receiving NOAC therapy had 233 fewer ischemic strokes (21.7%), 55 fewer deaths (1.1%), and 453 more major bleeding events (37.3%) over a 10-year simulation period. Per patient, these differences translated to approximately 1 additional quality-adjusted week of life (0.024 QALYs) with NOAC treatment during the 10-year simulation. When the 95% CIs of treatment effect sizes were considered in probabilistic sensitivity analysis, there was a 65.8% probability that NOAC treatment leads to more QALYs than withholding treatment.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this analytical model study, initiating NOACs in patients with device-detected subclinical AF was associated with a minimal increase in QALYs. However, the benefits were uncertain, and the effect size of the overall net benefit does not appear to be clinically meaningful.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.8461","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:30:45Z","timestamp":1746199845000},"page":"e258461","source":"Crossref","is-referenced-by-count":11,"title":["Net Benefit of Anticoagulation in Subclinical Device-Detected Atrial Fibrillation"],"prefix":"10.1001","volume":"8","author":[{"given":"Aleksi K.","family":"Winst\u00e9n","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, University of Turku, Turku, Finland"},{"name":"Faculty of Medicine, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Lang\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E. Juhani","family":"Airaksinen","sequence":"additional","affiliation":[{"name":"Turku University Hospital and University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konsta","family":"Teppo","sequence":"additional","affiliation":[{"name":"Heart Centre, Turku University Hospital, Turku, Finland"},{"name":"Department of Life Technologies, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"9921","key":"zoi250308r1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"zoi250308r2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"13","key":"zoi250308r3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes.","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250308r4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation.","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi250308r5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","article-title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials.","volume":"149","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"zoi250308r6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/eurheartj\/ehad771","article-title":"Anticoagulation with edoxaban in patients with long atrial high-rate episodes =24?h.","volume":"45","author":"Becher","year":"2024","journal-title":"Eur Heart J"},{"issue":"19","key":"zoi250308r7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehae225","article-title":"Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.","volume":"45","author":"Lip","year":"2024","journal-title":"Eur Heart J"},{"issue":"22","key":"zoi250308r8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.124.069903","article-title":"Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: insights from the ARTESiA trial.","volume":"150","author":"McIntyre","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"zoi250308r9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA.","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zoi250308r10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi250308r11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"zoi250308r12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/STROKEAHA.118.022913","article-title":"Long-term survival and function after stroke: a longitudinal observational study from the Swedish Stroke Register.","volume":"50","author":"Sennf\u00e4lt","year":"2019","journal-title":"Stroke"},{"issue":"4","key":"zoi250308r13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022638","article-title":"Ischemic stroke severity and mortality in patients with and without atrial fibrillation.","volume":"11","author":"Vinding","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"zoi250308r14","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"zoi250308r15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/STROKEAHA.111.630731","article-title":"Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.","volume":"43","author":"Fang","year":"2012","journal-title":"Stroke"},{"issue":"17","key":"zoi250308r16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036429","article-title":"Anticoagulation in patients with device-detected atrial fibrillation with and without a prior stroke or transient ischemic attack: the NOAH-AFNET 6 trial.","volume":"13","author":"Diener","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"zoi250308r17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages.","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"issue":"22","key":"zoi250308r18","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi250308r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137444","article-title":"Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and Vitamin K antagonists: a systematic review and meta-Analysis.","volume":"10","author":"Skaistis","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"zoi250308r20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","article-title":"Twenty-year change in severity and outcome of ischemic and hemorrhagic strokes.","volume":"79","author":"Toyoda","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi250308r21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12028-016-0279-1","article-title":"Predictors of functional outcome after subdural hematoma: a prospective study.","volume":"26","author":"Weimer","year":"2017","journal-title":"Neurocrit Care"},{"issue":"8","key":"zoi250308r22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1089\/neu.2018.6080","article-title":"Influence of antiplatelet and anticoagulant drug use on outcomes after chronic subdural hematoma drainage.","volume":"38","author":"Poon","year":"2021","journal-title":"J Neurotrauma"},{"issue":"8","key":"zoi250308r23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jama.2017.0639","article-title":"Association of antithrombotic drug use with subdural hematoma risk.","volume":"317","author":"Gaist","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"zoi250308r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20172","article-title":"Thirty-year incidence and mortality trends in upper and lower gastrointestinal bleeding in Finland.","volume":"3","author":"Vora","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi250308r25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174340","article-title":"All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis.","volume":"142","author":"Chornenki","year":"2023","journal-title":"Blood"},{"issue":"24","key":"zoi250308r26","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants.","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi250308r27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.healthpol.2005.06.011","article-title":"A comparison of individual and social time trade-off values for health states in the general population.","volume":"76","author":"Burstr\u00f6m","year":"2006","journal-title":"Health Policy"},{"issue":"18","key":"zoi250308r28","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","article-title":"Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study.","volume":"81","author":"Luengo-Fernandez","year":"2013","journal-title":"Neurology"},{"key":"zoi250308r29","doi-asserted-by":"publisher","author":"Teppo","journal-title":"Eur Heart J Qual Care Clin Outcomes","DOI":"10.1093\/ehjqcco\/qcac086"},{"issue":"12","key":"zoi250308r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49017","article-title":"Risk of intracranial hemorrhage associated with direct oral anticoagulation vs antiplatelet therapy: a systematic review and meta-analysis.","volume":"7","author":"Coyle","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi250308r32","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad166","article-title":"The influence of atrial high-rate episodes on stroke and cardiovascular death: an update.","volume":"25","author":"Toennis","year":"2023","journal-title":"Europace"},{"issue":"8","key":"zoi250308r33","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1253\/circj.CJ-20-1269","article-title":"Association between atrial high-rate episodes and ischemic\/major bleeding events in patients with a cardiac implantable electronic device\u2014a 10-year, single-center historical cohort study.","volume":"85","author":"Ishiguchi","year":"2021","journal-title":"Circ J"},{"key":"zoi250308r34","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","author":"Joglar","year":"2023","journal-title":"Circulation"},{"key":"zoi250308r35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO).","volume":"45(36)","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"zoi250308r36","doi-asserted-by":"publisher","author":"Gaudino","journal-title":"Eur Heart J","DOI":"10.1093\/eurheartj\/ehae478"},{"issue":"2","key":"zoi250308r37","doi-asserted-by":"publisher","first-page":"e1S","DOI":"10.1378\/chest.11-2290","article-title":"Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"MacLean","year":"2012","journal-title":"Chest"},{"issue":"6","key":"zoi250308r38","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/hex.12201","article-title":"Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.","volume":"18","author":"Alonso-Coello","year":"2015","journal-title":"Health Expect"},{"issue":"16","key":"zoi250308r39","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi250308r40","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2457522","article-title":"Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials.","volume":"57","author":"Lang\u00e9n","year":"2025","journal-title":"Ann Med"},{"key":"zoi250308r41","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70019-5","author":"Samsa","year":"1998","journal-title":"Am Heart J"},{"key":"zoi250308r31","unstructured":"Zenodo. Accessed April 15, 2025. https:\/\/zenodo.org\/records\/13323365"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833437\/winstn_2025_oi_250308_1745525888.9571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:30:46Z","timestamp":1746199846000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8461","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}